Read by QxMD icon Read

eradication of h. pylori

Yong Xie, Zhenhua Zhu, Jiangbin Wang, Lingxia Zhang, Zhenyu Zhang, Hong Lu, Zhirong Zeng, Shiyao Chen, Dongsheng Liu, Nonghua Lv
Objectives: To investigate the efficacy and safety of 10-day bismuth quadruple therapy with amoxicillin, tetracycline or clarithromycin and different doses of rabeprazole for first-line treatment of Helicobacter pylori infection. Methods: This multicenter, randomized, parallel-controlled clinical trial was conducted between March 2013 and August 2014. A total of 431 H. pylori -infected patients with duodenal ulcers were enrolled and randomized into four treatment groups (1:1:1:1) for 10 days: 1. LR-BAC Group, which received rabeprazole 10 mg b...
June 18, 2018: Antimicrobial Agents and Chemotherapy
Huo-Ye Gan, Tie-Li Peng, You-Ming Huang, Kai-Hua Su, Lin-Li Zhao, Li-Ya Yao, Rong-Jiao Yang
Bismuth + proton pump inhibitor (PPI) + amoxicillin + levofloxacin is one of the bismuth quadruple therapy regimens widely used for the eradication of H. pylori infection. The recommended dosage of levofloxacin is 500 mg once daily or 200 mg twice daily to eradicate H. pylori infection. The aim of the present open-label, randomized control trial was to compare the effectiveness, safety, and compliance of different dosages of levofloxacin used to cure Helicobacter pylori infection. Eligible patients were randomly assigned to receive esomeprazole, amoxicillin, colloidal bismuth pectin and levofloxacin 500 mg once/day (group A) or levofloxacin 200 mg twice/day (group B) for 14 days...
June 13, 2018: Scientific Reports
Young Woon Chang, Weon Jin Ko, Chi Hyuk Oh, Yoo Min Park, Shin Ju Oh, Jung Rock Moon, Jun-Hyung Cho, Jung-Wook Kim, Jae-Young Jang
Background/Aims: The eradication rate of the first-line triple therapy (a proton pump inhibitor, clarithromycin, and amoxicillin) for Helicobacter pylori infection has gradually decreased in Korea. We evaluated whether clinical parameters, clarithromycin resistance, and CYP2C19 genotype can affect the eradication failure. Methods: A total of 203 patients with H. pylori-positive chronic gastritis were consecutively enrolled. They received clarithromycin-based triple therapy for 7 days...
June 14, 2018: Korean Journal of Internal Medicine
Ping-I Hsu, Chao-Yu Pan, John Y Kao, Feng-Woei Tsay, Nan-Jing Peng, Sung-Shuo Kao, Huay-Min Wang, Tzung-Jiun Tsai, Deng-Chyang Wu, Chien-Lin Chen, Kuo-Wang Tsai
BACKGROUND: Bismuth quadruple therapy is the treatment of choice for the first-line therapy of Helicobacter pylori infection in areas of high clarithromycin resistance. Currently, the impact of the promising treatment on gut microbiota remains unclear. AIM: To investigate the short-term and long-term impacts of bismuth quadruple therapy on gut microbiota. METHODS: Adult patients with H. pylori-related gastritis were treated with 14-day bismuth quadruple therapy...
June 13, 2018: Helicobacter
Kyoichi Adachi, Tomoko Mishiro, Takashi Toda, Naomi Kano, Harumi Fujihara, Yuko Mishima, Atsuko Konishi, Mariko Mochida, Kazuko Takahashi, Yoshikazu Kinoshita
The purpose was to clarify the effects of Helicobacter pylori ( H. pylori ) eradication on the changes in serum lipid levels by comparing subjects with and without continuous H. pylori infection. The study subjects were 774 individuals (males 536, females 238, mean age 52.6 years) who visited between April 2013 and March 2016 for annual medical checkups. Serum total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), and triglyceride levels, and LDLC/HDLC ratio were compared between the subjects with and without H...
May 2018: Journal of Clinical Biochemistry and Nutrition
Hassan Salmanroghani, Massoud Mirvakili, Mahmud Baghbanian, Roham Salmanroghani, Golshid Sanati, Pouria Yazdian
AIM: To evaluate the efficacy and tolerability of tetracycline vs. high-dose amoxicillin in bismuth-based quadruple therapy for Helicobacter pylori(H. pylori) eradication. METHODS: This randomized, open-label clinical trial included 228 patients with H.pylori infection and duodenal ulcer without a history of H.pylori treatment. Patients were randomly divided into two groups. The amoxicillin group received metronidazole 500mg, bismuth subcitrate 240mg, and amoxicillin 1000mg, all three times a day, plus omeprazole 20 mg twice a day, for 14 days...
2018: PloS One
Sabine Skrebinska, Ilva Daugule, Daiga Santare, Sergejs Isajevs, Inta Liepniece-Karele, Dace Rudzite, Ilze Kikuste, Aigars Vanags, Ivars Tolmanis, Juris Atstupens, Jin Young Park, Rolando Herrero, Marcis Leja
OBJECTIVE: The aim of the study was to assess the accuracy of two plasma Helicobacter pylori (H. pylori) antibody test-systems and a stool antigen test (SAT) system in a general population sample in Latvia. MATERIALS AND METHODS: Blood and faecal samples were analysed in healthy individuals (40-64 years), referred for upper gastrointestinal endoscopy according to pilot study protocol within a population-based study investigating gastric cancer prevention strategies (GISTAR pilot study)...
June 11, 2018: Scandinavian Journal of Gastroenterology
Hui Ye, Zong-Ming Shi, Yao Chen, Jing Yu, Xue-Zhi Zhang
Helicobacter pylori (H. pylori) treatment requires the development of more effective therapies, mainly owing to the challenges posed by the bacterial resistance to antibiotics. In China, critically high infection and antibiotic resistance rates have limited the application of classic H. pylori eradication therapies. Consequently, researchers are attempting to find new solutions by drawing from traditional medicine. This article reviews basic scientific and clinical progress in the use of integrated Chinese and Western medicine (IM) to treat H...
June 8, 2018: Chinese Journal of Integrative Medicine
Kyoichi Adachi, Tomoko Mishiro, Eiko Okimoto, Yoshikazu Kinoshita
Aim To clarify the influence of the degree of gastric mucosal atrophy on the serum lipid levels before and after the eradication of Helicobacter pylori infection. Subjects and methods The subjects were individuals who underwent an annual detailed medical checkup. Serum anti-H. pylori IgG antibody detection and upper endoscopic examinations were performed in all subjects. Gastric mucosal atrophy was evaluated by the classification of Kimura and Takemoto. The serum levels of total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), LDLC/HDLC ratio, and triglycerides were compared among the different degrees of gastric mucosal atrophy in H...
June 6, 2018: Internal Medicine
Teruko Fukuda, Eri Asou, Kimiko Nogi, Masahiko Yasuda, Kazuo Goto
Strong evidence for an association between idiopathic thrombocytopenic purpura (ITP) and Helicobacter pylori (HP) infection has been reported in humans. Chronic ITP is known to be improved by the eradication of HP. The purpose of this study was to reproduce these events by the experimental infection of several strains of mice with HP. BALB/c, C57BL/6, and DBA/2 mice were untreated or orally inoculated with HP. Two months later, platelet counts were compared in samples from HP-infected and noninfected mice. Platelet counts (mean ± SD, × 104 )/μl) in blood samples from HP-infected BALB/c, C57BL/6, and DBA/2 mice were 102...
June 7, 2018: Experimental Animals
Luyi Chen, Jiamin He, Lan Wang, Qiwei Ge, Hua Chu, Yujia Chen, Xiaoli Chen, Yanqin Long, Yanyong Deng, Huiqin He, Aiqing Li, Shujie Chen
To evaluate potency and safety of 14-day bismuth-furazolidone quadruple regimens and to compare efficacies of five proton pump inhibitors (PPIs) for the initial eradication of Helicobacter pylori (H. pylori), 175 eligible patients were enrolled and randomly assigned to 14-day quadruple regimens consisting of bismuth (400 mg), amoxicillin (1 g), furazolidone (100 mg), and a PPI, twice a day. PPIs used were Group A (pantoprazole capsules, 40 mg), Group B (pantoprazole tablets, 40 mg), Group C (lansoprazole, 30 mg), Group D (esomeprazole, 20 mg), and Group E (rabeprazole, 10 mg)...
June 6, 2018: Clinical and Experimental Medicine
Aysel Ünlüsoy Aksu, Güldal Yılmaz, Ödül Eğritaş Gürkan, Sinan Sarı, Buket Dalgıç
BACKGROUND: The aim of this study was to evaluate the effect of Helicobacter pylori (H. pylori) eradication on dyspepsia symptom scores in children with functional dyspepsia (FD). MATERIALS AND METHODS: One hundred and fifty functional dyspeptic children (ages 8-18 years, mean: 13.3 ± 2.84 years; 30% male) were enrolled to this prospective study. Upper gastrointestinal endoscopy was performed on all patients, and the samples from the gastric antrum and corpus were obtained for the existence of H...
June 6, 2018: Helicobacter
Min Li, Tadayuki Oshima, Tomoki Horikawa, Katsuyuki Tozawa, Toshihiko Tomita, Hirokazu Fukui, Jiro Watari, Hiroto Miwa
BACKGROUND: Vonoprazan is a novel gastric acid suppressant that is applied in Japan to treat gastric diseases including Helicobacter pylori (H. pylori) infection. This meta-analysis aimed to summarize the ability of vonoprazan to eradicate clarithromycin-susceptible and clarithromycin-resistant H. pylori strains. MATERIALS AND METHODS: A systematic search was performed using PubMed, EMBASE, Web of Science, and Cochrane Library. Studies were included if they evaluated eradication rates of vonoprazan-based and conventional PPI-based triple therapies and checked for clarithromycin susceptibility of H...
June 6, 2018: Helicobacter
Benjamin Blümel, Hanna Goelz, Manfred Kist, Erik-Oliver Glocker
BACKGROUND: Antimicrobial susceptibility of Helicobacter (H.) pylori is usually determined by phenotypic methods. When H. pylori cannot be grown owing to contaminations or delay in transport of gastric tissue samples to the microbiological laboratory, molecular genetic testing is a reasonable alternative. The aim of this retrospective study was to assess the outcome of salvage eradication treatments based on molecular genetic susceptibility testing. METHODS: Data on 144 H...
June 6, 2018: Helicobacter
Yu Hatano, Ken Haruma, Tomoari Kamada, Akiko Shiotani, Kosuke Takahari, Masatoshi Matsumoto, Osamu Uchida
BACKGROUND/AIMS: Previous studies have reported a possible relevance between proton pump inhibitor (PPI) use and 3 new gastric mucosal changes: black spots (BSs), white flat elevated mucosa (WFEM), and cobblestone-like mucosa (CLM). The aim of this study was to investigate the association between these mucosal changes and multiple factors including PPI use. METHODS: All subjects who underwent a routine esophagogastroduodenoscopy (EGD) were successively enrolled...
June 5, 2018: Digestion
Doron Boltin, Hemda Schmilovitz-Weiss, Rachel Gingold-Belfer, Haim Leibovitzh, Yifat Snir, Tsachi Tsadok Perets, Ram Dickman, Zohar Levi, Yaron Niv
BACKGROUND/AIMS: Although the efficacy of first-line treatment for Helicobacter pylori infection should aim to be > 90%, it is unclear whether this target has been achieved in Israel. We aimed to determine the success rate of treatment for H. pylori and to describe temporal changes in our region. Methods: Adult patients who underwent a first-time -C13-urea breath test (C13-UBT) at Clalit Health Services between January 1, 2010 and December 31, 2015 were included. In order to isolate a naïve "test-and-treat" population who were unlikely to have undergone an initial endoscopy-based H...
June 5, 2018: Digestion
Xing Pan, Hong Ke, Xiaojuan Niu, Shan Li, Jun Lv, Longrui Pan
Vaccination is an increasingly important alternative approach to control Helicobacter pylori infection, since H. pylori resistance to previously efficacious antibiotic regimens is increased, and H. pylori eradication treatment for upper gastrointestinal diseases is becoming less successful. Fortunately, an efficient oral monovalent H. pylori vaccine has been developed. However, compared with monovalent vaccines, multivalent vaccines have the potential to induce more effective and comprehensive protection against H...
2018: Frontiers in Immunology
Byung Hak Jin, Byung Won Yoo, Jungsin Park, Jung Hye Kim, Jun Yeon Lee, Jae Soo Shin, Min Soo Park
PURPOSE: Ilaprazole, the latest proton pump inhibitor, can be used with clarithromycin and amoxicillin as a triple therapy regimen for eradicating Helicobacter pylori. The aim of this study was to evaluate pharmacokinetic drug interactions and safety profiles after coadministration of clarithromycin, amoxicillin, and ilaprazole. METHODS: A randomised, open-label, one-way crossover, two parallel sequences study was conducted in 32 healthy subjects. In part 1, the subjects received a single dose of ilaprazole 10 mg in period 1 and clarithromycin 500 mg and amoxicillin 1000 mg twice daily for 6 days in period 2...
May 30, 2018: European Journal of Clinical Pharmacology
Jyh-Ming Liou, Chieh-Chang Chen, Yu-Jen Fang, Po-Yueh Chen, Chi-Yang Chang, Chu-Kuang Chou, Mei-Jyh Chen, Cheng-Hao Tseng, Ji-Yuh Lee, Tsung-Hua Yang, Min-Chin Chiu, Jian-Jyun Yu, Chia-Chi Kuo, Jiing-Chyuan Luo, Wen-Feng Hsu, Wen-Hao Hu, Min-Horn Tsai, Jaw-Town Lin, Chia-Tung Shun, Gary Twu, Yi-Chia Lee, Ming-Jong Bair, Ming-Shiang Wu
Background: Whether extending the treatment length and the use of high-dose esomeprazole may optimize the efficacy of Helicobacter pylori eradication remains unknown. Objectives: To compare the efficacy and tolerability of optimized 14 day sequential therapy and 10 day bismuth quadruple therapy containing high-dose esomeprazole in first-line therapy. Methods: We recruited 620 adult patients (≥20 years of age) with H. pylori infection naive to treatment in this multicentre, open-label, randomized trial...
May 29, 2018: Journal of Antimicrobial Chemotherapy
Chonticha Auesomwang, Monthira Maneerattanaporn, William D Chey, Pattarachai Kiratisin, Somchai Leelakusolwong, Tawesak Tanwandee
BACKGROUND/AIM: Eradication rates of Helicobacter pylori following standard triple therapy are declining worldwide, but high-dose proton-pump inhibitor-based triple therapy (HD-PPI-TT) and sequential therapy (ST) have demonstrated higher cure rates. We aimed to compare the efficacy and tolerability of HD-PPI-TT and ST in H. pylori-associated functional dyspepsia (HP-FD). METHODS: One hundred and twenty HP-FD patients were randomized to receive 10-day HD-PPI-TT (60 mg lansoprazole/500 mg clarithromycin/1 g amoxicillin, each administered twice daily for 10 days) or 10-day ST (30 mg lansoprazole/1 g amoxicillin, each administered twice daily for 5 days followed by 30 mg lansoprazole/500 mg clarithromycin/400 mg metronidazole, each administered twice daily for 5 days)...
May 27, 2018: Journal of Gastroenterology and Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"